LoQus23 Therapeutics exits stealth with GBP11.5m seed financing from the Dementia Discovery Fund and Novartis Venture Fund
LoQus23 Therapeutics (LoQus23), a company discovering small molecule therapies that target aberrant DNA mismatch repair (MMR) to treat Huntington’s and other triplet repeat diseases (TRDs), has closed its GBP7 million extended seed round. LoQus23 secured the financing from Novartis Venture Fund (NVF) and its founding investor the Dementia Discovery Fund